Gallic acid

Cat. No.: HY-N0523
CAS No.: 149-91-7
Molecular Formula: C₇H₆O₅
Molecular Weight: 170.12
Target: COX
Pathway: Immunology/Inflammation
Storage: Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro
DMSO : 100 mg/mL (587.82 mM; Need ultrasonic and warming)

Preparation of Stock Solutions

<table>
<thead>
<tr>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>5.8782 mL</td>
<td>29.3910 mL</td>
<td>58.7820 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>1.1756 mL</td>
<td>5.8782 mL</td>
<td>11.7564 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.5878 mL</td>
<td>2.9391 mL</td>
<td>5.8782 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
Gallic acid is an antioxidant which can inhibit both COX-2.

IC₅₀ & Target
COX-2

In Vitro
Gallic acid is an antioxidant which can inhibit both COX-2.[1] After 18 h treatment with Gallic acid, the number of viable neutrophils is dramatically decreased from 40.3% to 27.7%, highly comparable with 26.4% for untreated neutrophils. Gallic acid fails to attenuate isoproterenol-induced myocytolysis.[3]

In Vivo
The food intake (2.6±0.08 g/day, p=0.69) and the body weight (2.5±0.69 g, p=0.76) of the Gallic acid group do not differ significantly from those of the control group (food intake; 2.41±0.14 g/day and the body weight; 2.83±0.84 g/day). The blood glucose tolerance in the Gallic acid group is significantly improved after 2 weeks of treatment. The blood glucose tolerance of the Gallic acid group after a treatment period of 2 weeks is also significantly better than that of the control group at 90 and 120 min (p<0.05). The serum triglyceride concentration in the Gallic acid group (0.67±0.03 mM, p<0.05) is significantly reduced relative to that of the control group (1.08±0.20 mM). The total
cholesterol concentration is similar in the control (3.19±0.27 mM) and Gallic acid (3.01±0.18 mM) groups\cite{2}.

**PROTOCOL**

**Cell Assay**\cite{3}

Neutrophils are treated with 8 \( \mu g/mL \) Gallic acid in RPMI1640/10% FBS for 3, 6, 9, and 18 h. At the end of Gallic acid treatment, the cells are stained with Annexin V-FITC and PI according to manufacturer’s instructions. Briefly, the cells are washed twice with ice-cold PBS and resuspended in 1× Binding Buffer at a concentration of 1×10^6 cells/mL. Cell suspensions (1×10^5 cells in 100 \( \mu L \)) are incubated with 5 \( \mu L \) of Annexin V-FITC and 10 \( \mu L \) PI in a 5 mL culture tube at room temperature for 20 min. The stained cells are immediately analyzed on flow cytometry system\cite{3}. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**Animal Administration**\cite{2}

Five-week-old male C57BL/6 mice are used in this study. The animals are maintained in a temperature-controlled room at 22° C on a 12 h light-dark photocycle. The mice are divided into the control vehicle group and the Gallic acid group. For 2 weeks, the mice are administered intraperitoneal treatment on a daily basis with vehicle (10% alcohol, 10% tween 80, and 80% saline) alone or with 10 mg/kg Gallic acid. After this treatment, GTTs are again conducted, and the blood samples are taken for subsequent biochemical analysis. Over the experimental period, food intake and body weight are measured on a daily basis\cite{2}. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**REFERENCES**


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA